Table 2.
Characteristics | Number of patients | Number of deaths (%) |
---|---|---|
Last known status | ||
Dead | 78 (7.3%) | |
Alive | 820 (76.9%) | |
Loss to followup (LTFU) | 168 (15.6%) | |
Age group (years) | ||
15–24 | 39 | 1 (2.5) |
25–34 | 354 | 15 (4.2) |
35–44 | 442 | 39 (7.0) |
45+ | 234 | 39 (13.3) |
Baseline CD4 staging (cells/μL) | ||
>500 | 312 | 10 (3.2) |
350–499 | 134 | 3 (2.2) |
200–349 | 111 | 3 (2.7) |
<200 | 512 | 62 (12.1) |
Drug regimen | ||
Combivir-based 1st line | 383 | 15 (3.9) |
Truvada-based 1st line | 548 | 55 (10.0) |
Combivir-based 2nd line | 67 | 2 (2.0) |
Truvada-based 2nd line | 53 | 2 (3.8) |